

REFERENCES

- Al-Riyami A, Hayness LG, Campbell AM. The construction of a monoclonal diagnosis system for the field detection of *V. cholerae*. FEMS Microbiol Immunol 1991; 76: 25-32.
- Barrett TJ, Blake PA. Epidemiological usefulness of changes in hemolytic activity of *Vibrio cholerae* biotype El Tor during the seventh pandemic. J Clin Microbiol 1981; 13: 126-29.
- Baumann P, Furniss AL, Lee JV. *Vibrio*. In: Bergey's Manual of Systemic Bacteriology, vol 1, Krieg NR, Holt JG (eds.). Williams and Wilkins. Baltimore and London, 1984.
- Benenson AS, Islam MR, Greenough WB. Rapid identification of *Vibrio cholerae* by darkfield microscopy. Bull WHO 1964; 30: 827-31.
- Bellamy JE, Knop J, Steele EJ, Chaicumpa W, Rowley D. Antibody cross-linking as a factor in immunity to cholera in infant mice. J Infect Dis 1975; 132: 181-88.
- Briskin M, Rott L, Butcher EC. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptors $\alpha 4\beta 7$, common themes among integrin-Ig family interaction. J Immunol 1996; 156: 719-26.
- Briskin M, Winsor-Hines D, Shyjan A, *et al.* Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
- Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-66.
- Center of Diseases Control. Cholera-New York, 1991. Morbid Mortal Weekly Rep 1991; 40: 516-18.
- Chaicumpa W, Srimanote P, Sakolvaree Y, *et al.* Rapid diagnosis of cholera caused by *Vibrio cholerae* O139. J Clin Microbiol 1998; 36: 3595-600.
- Chaicumpa W, Thattiyaphong A, Supawat K, *et al.* Rapid detection of *V. cholerae* O1. Serodiagnosis and Immunother of Infections Disease 1995b; 7: 161-72.

- Chaicumpa W, Thin-inta W, Kusmith S, *et al.* Detection with monoclonal antibody of *Salmonella typhi* antigen 9 in specimens from patients. *J Clin Microbiol* 1988; 26: 1824-30.
- Chaing SL, Mekalanos JJ. *rfb* mutation in *V. cholerae* do not affect surface production of toxin-coregulated pili but still inhibit intestinal colonization. *Infect Immun* 1999; 67: 976-80.
- Champion GA, Neely MN, Brennan MA, Dirita VJ. A branch in the ToxR regulatory cascade of *Vibrio cholerae* revealed by characterization of *toxT* mutant strains. *Mol Microbiol* 1997; 23: 323-31.
- Chongsa-nguan M, Chaicumpa W, Moolasart P, *et al.* *Vibrio cholerae* O139 Bengal in Bangkok. *Lancet* 1993; 342:430-31.
- Communicable Diseases Control Department, Ministry of Public Health. Situation of Infectious Disease Monthly Reports. Thailand, 2000.
- Cohen J. A coefficient of agreement for nominal scale. *Educ Psychol Meas* 1960; 20: 37-46.
- Cohen J, Schwartz T, Klasmer R, Pridan D, Ghalayini H, Davies AM. Epidemiology aspects of cholera El Tor outbreak in a non-endemic area. *Lancet* 1971; ii: 86-89.
- Cowell RR, Hasan JAK, Huq A, *et al.* Development and evaluation of rapid, simple, sensitive, monoclonal antibody-based coagglutination test for direct detection of *Vibrio cholerae* O1. *FEMS Microbiol Letters* 1992; 97: 215-20.
- Cholera Working Group. Large epidemic of cholerae-like disease in Bangladesh caused by *Vibrio cholerae* O139 synonym Bengale. Cholera Working Group. *Lancet*. 1993; 342: 387-90.
- Clemens JD, Sack DA, Harris JR, *et al.* Field trial of oral cholera vaccines in Bangladesh. *Lancet* 1986; 2: 124-27.
- Coster TS, Killeen KP, Waldor MK, *et al.* Safety, immunogenicity, and efficacy of live attenuated *Vibrio cholerae* O139 vaccine prototype. *Lancet* 1995; 345: 949-52.
- Crawford JA, Kaper JB, Dirita VJ. Analysis of ToxR-dependent transcription activation of *ompU*, the gene encoding a major envelope protein in *V. cholerae*. *Mol Microbiol* 1998; 29: 235-46.

- CWG. Large epidemic of cholerae-like disease in Bangladesh caused by *Vibrio cholerae* O139 synonym Bengale. Cholerae Working Group. Lancet. 1993; 342: 387-90.
- Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 5th edition. John Wiley and Sons, 1991; 155-57.
- David KRK, Judith AJJ, Camella CB, Edgar CB, James BK, Peter RR. A *Vibrio cholerae* pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci 1998; 95: 3134-39.
- Dirita VJ, Neely M, Taylor RK, Bruss PM. Differential expression of the ToxR regulon in classical and El Tor biotypes of *Vibrio cholerae* is due to biotype-specific control over *toxT* expression. Proc Natl Acad Sci USA 1996; 93: 7991-95.
- Division of Epidemiology. Annual epidemiological surveillance report. Division of Epidemiology, Office of Permanent Secretary for Public Health, Ministry of Public Health, Nonthaburi, Thailand, 1993-99.
- Division of Epidemiology. Annual epidemiological surveillance report. Division of Epidemiology, Office of Permanent Secretary for Public Health, Ministry of Public Health, Nonthaburi, Thailand, 2005-06.
- Ehrhardt RO, Strober W, Harriman GR. Effect of transforming growth factor (TGF- β) on IgA isotype expression. TGF- β induces a small increase in sIgA⁺ B cells regardless of the method of B cell activation. J Immunol 1992; 148: 3830-36.
- Falkow S, Mekalanos J. The enteric bacilli and vibrios. In: Davis BD, Dulbecco R, Elson HN, Ginsberg HS. (eds.). Microbiology 4th ed. Harper International edition, Singapore 1990; 582-86.
- Farstad IN, Halstensen TS, Lien B, Hkilstad PJ, Lazarovits AI, Brandtzaeg P. Distribution of α 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunology 1996; 89: 227-37.
- Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology genetics and ecology of toxigenic *Vibrio cholerae*. Microbiol Mol Biol Rev 1998; 62: 1301-14.
- Faruque SM, Ahmed MK, Siddique KA, Zaman K, Alim RMAR, Albert MJ. Molecular analysis of toxigenic *Vibrio cholerae* O139 Bengal isolated in

- Bangladesh between 1993 and 1996: evidence for the emergence of a new clone of the Bengal vibrios. *J Clin Microbiol* 1997; 35: 2299-106.
- Fasano A, Baudry B, Pumphlin DW, *et al.* *Vibrio cholerae* produces a second enterotoxin, which affects intestinal tight junctions. *Proc Natl Acad Sci USA* 1991; 88: 5242-46.
- Fields PI, Popovic T, Wachsmuth K, Olsvik O. Use of polymerase chain reaction for detection of cholera toxigenic *Vibrio cholerae* O1 strains from the Latin American cholera epidemic. *J Clin Microbiol* 1992; 30: 2118-21.
- Finkelstein RA, Labrec EH. Rapid identification of cholera vibrios with fluorescent antibody. *J Bacteriol* 1959; 78: 886-91.
- Galen RS. The predictive values and efficiency of laboratory testing. *Pediatr Clin N Am* 1980; 27: 861-69.
- Goodgame RW, Greenough WB. Cholera in Africa: a message for the West. *Ann Intern Med* 1975; 82: 101-06.
- Greenough WB, Benenson AS, Islam MR. Experience of darkfield examination of stools from diarrhoeal patients. In: *Proceedings Cholera Research Symposium, 1965; 24-26, Honolulu, U.S. Government Printing Office, Washington D.C. 1965; 56-58.*
- Gupta RK, Siber GR. Adjuvants for human vaccines- current status, problems and future prospects. *Vaccine* 1995; 13: 1263-76.
- Gustafsson B. Monoclonal antibody-based enzyme-linked immunosorbent assays for identification and serotyping of *Vibrio cholerae* O1. *J Clin Microbiol* 1984; 20: 1180-85.
- Gustafsson B, Holme T. Monoclonal antibodies against group and type-specific lipopolysaccharide antigens of *Vibrio cholerae* O1. *J Clin Microbiol* 1983; 18: 480-85.
- Gustafsson B, Holme T. Rapid detection of *Vibrio cholerae* O1 by motility inhibition and immunofluorescence with monoclonal antibodies. *Eur J Clin Microbiol* 1985; 4: 291-94.
- Gustafsson B, Rosen A, Holme T. Monoclonal antibodies against *Vibrio cholerae* lipopolysaccharide. *Infect Immun* 1982; 38: 449-54.

- Hasan JAK, Huq A, Tamplin M, *et al.* Decrease in net output in children during intestinal profusion with glucose-containing solution. *N Eng J Med* 1968; 279: 176-81.
- Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the *toxR* regulon are essential for *Vibrio cholerae* pathogenesis in human. *J Exp Med* 1988; 168: 1487-92.
- Holmgren J, Svennerholm A. Development of oral vaccines against cholera and enterotoxinogenic *Escherchia coli* diarrhea. *J Infect Dis (Suppl)* 1990; 76: 47-53.
- Honda T, Finkelstein RA. Purification and characterization of a hemolysin produced by *Vibrio cholerae* biotype El Tor; another toxic substance produced by cholera vibrios. *Infect Immun* 1979; 26: 1020-27.
- Huq A, Colwell RR, Rahmann R, *et al.* Detection of *Vibrio cholerae* O1 in the aquatic environment by fluorescent-monoclonal antibody and culture methods. *Appl Environ Microbiol* 1990; 56: 2370-73.
- Ichinose Y, Yamamoto K, Nakasone N, *et al.* Enterotoxicity of El Tor-like hemolysin of non-O1 *Vibrio cholerae*. *Infect Immun* 1987; 55: 1090-93.
- Iredii JR, Strocher UH, Ward HM, Manning PA. Lipopolysaccharide O-antigen expression and the effect of its absence on virulence in *rfb* mutants of *V. cholerae* O1. *FEMS Immuno Med Microbiol* 1998; 20: 45-54.
- Jesudason M, Thangavelu CP, Lalitha MK. Rapid screening of faecal samples for *Vibrio cholerae* by a coagglutination technique. *J Clin Microbiol* 1984; 19: 712-13.
- Kantale A, Kantele JM, Savilahti E, *et al.* Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. *J Immunol* 1997; 158: 574-79.
- Kaper JB, Morris JG, Levine MM. Cholera. *Clin Microbiol Rev* 1995; 8: 48-86.
- Kaper JB, Moseley SL, Falkow S. Molecular characteristic of environmental and nontoxigenic strains of *Vibrio cholerae*. *Infect Immune* 1981; 32: 661-67.

- Kaysner CA, DePaola A-Jr. Bacteriological analysis manual online. Chapter 9 *Vibrio*. 2004, FDA/Center for Food Safety & Applied Nutrition, U.S. Food and drug Administration. <http://www.cfsan.fda.gov/~ebam/bam-9.html>. Accessed on January 20, 2006.
- Keasler SP, Hall RH. Detection and biotyping of *Vivrio cholerae* O1 with multiplex polymerase chain reaction. *Lancet* 1993; 341: 1661.
- Kelly MT, Hickmann-Brenner FW, Farmer III JJ. *Vibrio*. In: Lanette EH *et al.* (eds.). *Manual of Clinical Microbiology*. 4th ed. American Society for Microbiology, Washington D.C. 1985.
- Kirn TJ, Lafferty MJ, Sandoe CM, Taylor RK. Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by *Vibrio cholerae*. *Mol Microbiol* 2000; 35(4): 896-910.
- Koch R. An address on cholera and its bacillus. *Br Med J* 1884; 1884: 403-07.
- Koch WH, Payne WL, Wentz BA, Cebul TA. Rapid polymerase chain reaction method for detection of *Vibrio cholerae* in foods. *Appl Environ Microbiol* 1993; 59: 556-60.
- Kovacikova G, Skorupski K. A *Vibrio cholerae* LysR homolog, AphB, cooperates with AphA at the *tcpPH* promoter to activate expression of the ToxR virulence cascade. *J Bacteriol* 1999; 181: 4250-56.
- Krukonis ES, Yu RR, DiRita VJ. The *Vibrio cholerae* ToxR/TcpP/ToxT virulence cascade: distinct roles for two membrane-localized transcriptional activators on a single promoter. *Mol. Microbiol* 2000; 38: 67-84.
- Landish JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1997; 159-74.
- Laval E. El colera en Chile (1886-1888). *Rev Chil Infect* 1989; 6: 96-99.
- Levine MM. South America: the return of cholera. *Lancet* 1991; 338: 45-46.
- Levine MM, Kaper JB, Herrington D, *et al.* Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD103 and CVD103-HgR. *Lancet* 1988; 2: 467-70.
- Li CC, Crawford JA, Dirita VJ, Kaper JB. Molecular cloning and transcription regulation of *ompT*, a ToxR-repressed gene in *V. cholerae*. *Mol Microbiol* 2000; 35: 189-203.

- Manrong L, Toshio S, Glenn J, Morris JR, Alexander S, Shanmuga S. Evidence for the emergence of Non-O1 and Non-O139 *Vibrio cholerae* strains with pathogenic potential by exchange of O-antigen biosynthesis regions. *Infect and Immun* 2002; 70: 2441–53.
- McGhee JR, Lamm ME, Strober W. Mucosal immune responses. In: McGhee JR. (ed.). *Mucosal Immunology* 1999; 485-506.
- Mekalanos JJ, Rubin JE, Waldor KM. Cholera: molecular basis for emergence and pathogenesis. *FEMS Immuno Med Microbiol* 1997; 18: 241-48.
- Mindy JP, Gloria A, Cheryl B, *et al.* Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health importance in the developing world. WHO/CDS/CSR/RMD 2003; 6: 143.
- Mitra RK, Nandy RK, Ramamurthy T, *et al.* Molecular characterization of rough variants of *Vibrio cholerae* isolated from hospitalized patients with diarrhea. *J Med Microbiol* 2001; 50: 268-76.
- Monsur KA, Rizvi SSH, Huq MI. Effect of Mukerjee's Group IV phage on El Tor vibrios. *Bull WHO* 1965; 32: 211-16.
- Mukerjee S. Principle and practice of typing of *Vibrio cholera*. In : Bergen T, Norris JR. (eds.) *Method in Microbiology*. Vol. 12. Academic Press Inc. New York. 1978; 51-115.
- Mukerjee S, Roy G. Evaluation of tests for differentiating *Vibrio cholerae* and El Tor vibrios. *Ann Biochem Exp Med* 1961; 21: 129-32.
- Mukhopadhyay AK, Basu A, Garg P, *et al.* Molecular epidemiology of reemergent *Vibrio cholerae* O139 Bengal in India. *J Clin Microbiol* 1998; 36: 2149-52.
- Nair GB, Shimada T, Karazono H, *et al.* Characterization of phenotypic, serotypic, and toxigenic traits of *Vibrio cholerae* O139 Bengal. *J Clin Microbiol* 1994; 32: 2775-79.
- Nataro JP, Levine MM. Enteric bacterial vaccines: *Salmonella*, *Shigella*, Cholera, *Escherichia coli*. In: McGhee JR, editor. *Mucosal Immunology*; 1999; 851-66.
- Nesper J, Lauriano CM, Klose KE, Kraib A, Reid A. Characterization of *V. cholerae* O1 El Tor *galU* and *galE* mutants: influence on lipopolysaccharide, colonization and biofilm-formation. *Infect Immun* 2001; 69: 435-45.

- Nina NM, Nicholas AD, Alyssa NE, *et al.* A survey of stool culturing practices for *Vibrio* species at clinical laboratories in gulf coast states. *J Clin Microbiol* 2000; 38: 2267-70.
- Nishikawa Y, Hase A, Ishii E, Kishi T. Screening of aquatic samples for *V. cholerae* serotype O1 by a dot-blot method and a latex agglutination test. *Appl Environ Microbiol* 1990; 56: 1547-50.
- Pan American Health Organization. Cholera situation in the Americas. *Epidemiol Bull* 1991; 12: 1-4.
- Pavia AT, Bryan JA, Maher KL, Hester TR Jr, Farmer JJ III. *Vibrio carchariae* infection after a shark bite. *Ann Intern Med* 1989; 111: 85-86.
- Pearson GDN, Woods S, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. *Proc Natl Acad Sci USA* 1993; 90: 3750-54.
- Provenzano D, Klose KE. Altered expression of the *toxR*-regulated porins *ompU* and *ompT* diminishes *Vibrio cholerae* bile resistance, virulence factors expression, and intestinal colonization. *Proc Natl Acad Sci USA* 2000; 97: 10220-24.
- Provenzano D, Lauriano CM, Klose KE. Characteristic of the role of the *ToxR*-modulated outer membrane porins OmpU and OmpT in *Vibrio cholerae*. *J Bacteriol* 2001; 183: 3652-62.
- Qadri F, Chowdhury A, Hossain J, *et al.* Development and evaluation of rapid monoclonal antibody-based coagglutination test for direct detection of *V. cholerae* O139 synonym Bengal in stool samples. *J Clin Microbiol* 1994; 32: 1589-90.
- Rahman M, Sack DA, Waddood M, *et al.* Rapid identification of *V. cholerae* serotype O1 from primary isolation plates by a coagglutination test. *J Med Microbiol* 1989; 38: 39-41.
- Ramamurthy T, Garg S, Sharma R, *et al.* Emergence of a novel strain of *Vibrio cholerae* with epidemic potential in Southern and Eastern India. *Lancet* 1993; 341: 703-04.
- Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphtherique. *Bull Soc Centr Med Vet* 1925; 101: 227-34.

- Ramon G. Procedres pour acroitre la production des antitoxines. Ann Institut Pasteur 1926; 40: 1-10.
- Reidl J, Klose KE. *Vibrio cholerae* and cholera: out of the water and into the host. FEMS Microbiol Rev 2002; 26: 125-39.
- Ries AA, Vugia JD, Beingolea L, *et al.* Cholera in Piura, Peru: a modern urban epidemic. J Infect Dis 1992; 166: 1429-33.
- Rivera ING, Chun J, Huq A, *et al.* Genotypes associated with virulence in Environmet isolates of *Vibrio cholerae*. Appl Env Microbiol 2001; 2421-29.
- Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 2000; 31: 561-65.
- Sakazaki R, Donovan TJ. Serology and epidemiology of *V. cholerae* and *V. mimicus*. In: Bergan T. (ed.) Methods in Microbiology, Academic Press, London 1982; 16: 271-89.
- Sanchez JL, Vasquez B, Begue RE, *et al.* Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344: 1273-76.
- Santiago FG, Melissa JK, Michael EN, Ysabel S, Doughglas RC. Simultaneous detection of marine fish pathogens by using multiplex PCR and DNA microarray. J Clin Microbiol 2004; 42: 1414-19.
- Satcher D. Emerging infection: getting ahead of the cure. Emerg Infect Dis 1995; 1: 1-6.
- Schuhmacher DA, Klose KE. Environmental signals modulate *toxT*-dependent virulence factor expression in *Vibrio cholerae*. J Bacteriol 1999; 181: 1508-14.
- Sciortino CV, Yang Z, Finkelstein RA. Monoclonal antibodies to outer membrane antigens of *Vibrio cholerae*. Infect Immun 1985; 49: 122-31.
- Shimada T, Nair GB, Deb CB, Albert MJ, Sack BR, Takeda Y. Out break of *Vibrio cholerae* non-O1 in India and Bangladesh. Lancet 1993; 341: 1347.
- Shimada T, Sakazaki R. A serogroup of non-O1 *V. cholerae* possessing the Inaba antigen of *V. cholerae* O1. J Appl Bacteriol 1988; 64: 141-44.
- Shimada T, Sakazaki R, Mizushima M, *et al.* Two serogroups of *V. cholerae* non-O1 possessing somatic antigen factors in common with Hakata serogroup of *V. cholerae*. Jpn J Med Sci Biol 1990; 43: 1-6.

- Shirai H, Nichibuchi M, Ramamurthy T, *et al.* Polymerase chain reaction for detection of cholera enterotoxin operon of *Vibrio cholerae*. *J Clin Microbiol* 1991; 29: 2517-21.
- Siddique AK, Salam A, Islam SK, *et al.* Why treatment centres failed to prevent cholera death among Rwandan refugees in Goma, Zaire. *Lancet* 1995; 345: 359-61.
- Simonson JG, Siebeling RJ. Coagglutination of *V. cholerae*, *V. mimicus*, and *V. vulnificus* with an anti-flagella monoclonal antibody. *J Clin Microbiol* 1988; 26: 1962-66.
- Sugiyama J, Gondaira F, Matsuda J, Soga M, Terada Y. New method for serological typing of *V. cholerae* O1 using a monoclonal antibody-sensitized latex agglutination test. *Microbiol Immunol* 1987; 31: 387-91.
- Swerdlow DL, Ries AA. *Vibrio cholerae* non-O1 the-eight pandemic. *Lancet* 1993; 342: 382-83.
- Tacket CO, Losonsky G, Nataro JP, *et al.* Initial clinical studies of CVD112 *Vibrio cholerae* O139 live oral vaccine: safety and efficacy against experimental challenge. *J Infect Dis* 1995; 172: 883-86.
- Tacket CO, Losonsky G, Nataro JP, *et al.* Safety and immunogenicity of oral cholera vaccine candidate CVD110, a $\Delta ctxA$, Δzot , Δace derivative of El Tor Ogawa *Vibrio cholerae*. *J Infect Dis* 1993; 168: 1536-40.
- Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of *phoA* gene fusion to identify a pilus colonization factor coordinately regulated with cholera toxin. *Proc Natl Acad Sci USA* 1987; 84: 2833-37.
- Tiisala S, Paavonen T, Renkonen R. $\alpha\beta 7$ and $\alpha 4\beta 7$ integrins associated with intraepithelial and mucosa homing are expressed on macrophages. *Eur J Immunol* 1995; 25: 411-17.
- Trucksis M, Galen JE, Michalski J, Fasano A, Kaper JB. Accessory cholera enterotoxin (Ace), the third toxin of a *Vibrio cholerae* virulence cassette. *Proc Natl Acad Sci USA* 1993; 90: 5267-71.
- Van GFW, Nguyen HN, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. *Emerg Infect Dis* 2000; 6: 123-32.

- Varela P, Pollevick GD, Rivas M, *et al.* Direct detection of *Vibrio cholerae* in stool samples. *J Clin Microbiol* 1994; 32: 1246-48.
- Varela P, Rivas M, Binsztein N, *et al.* Identification of toxigenic *Vibrio cholerae* from the Argentina out break by PCR for *ctxA1* and *ctx2-B*. *FEBS Lett* 1993; 315: 74-76.
- Xu HS, Robert NC, Adams BL, *et al.* An indirect fluorescent antibody staining procedure for detection of *Vibrio cholerae* serovar O1 cells in aquatic environmental samples. *J Microbiol* 1992; 6: 221-31.
- Yamamoto K, Takeda Y, Miwatani T, Craig J P. Evidence that a non-O1 *Vibrio cholerae* produce enterotoxin that is similar but not identical to cholerae enterotoxin. *Infect Immuno* 1983; 41: 896-901.
- Waldor KW, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. *Science* 1996; 272: 1910-14.
- Wei L, Karla JF, Rebecca C, *et al.* Identification of a *Vibrio cholerae* RTX toxin gene cluster that is tightly linked to the cholera toxin prophage. *Proc Natl Acad Sci* 1999; 96: 1071-76.